Home
>
National Drug Code (NDC)
>
Cytarabine
Cytarabine - 61703-319-22 - (CYTARABINE)
Drug Information of Cytarabine
| Product NDC: | 61703-319 |
| Proprietary Name: | Cytarabine |
| Non Proprietary Name: | CYTARABINE |
| Active Ingredient(s): | 100 mg/mL & nbsp; CYTARABINE |
| Administration Route(s): | INTRATHECAL; INTRAVENOUS; SUBCUTANEOUS |
| Dosage Form(s): | INJECTION, SOLUTION |
| Coding System: | National Drug Codes(NDC) |
Labeler Information of Cytarabine
| Product NDC: | 61703-319 |
| Labeler Name: | Hospira Worldwide, Inc. |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | ANDA075383 |
| Marketing Category: | ANDA |
| Start Marketing Date: | 19991122 |
Package Information of Cytarabine
| Package NDC: | 61703-319-22 |
| Package Description: | 1 VIAL, SINGLE-DOSE in 1 CARTON (61703-319-22) > 20 mL in 1 VIAL, SINGLE-DOSE |
NDC Information of Cytarabine
| NDC Code | 61703-319-22 |
| Proprietary Name | Cytarabine |
| Package Description | 1 VIAL, SINGLE-DOSE in 1 CARTON (61703-319-22) > 20 mL in 1 VIAL, SINGLE-DOSE |
| Product NDC | 61703-319 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | CYTARABINE |
| Dosage Form Name | INJECTION, SOLUTION |
| Route Name | INTRATHECAL; INTRAVENOUS; SUBCUTANEOUS |
| Start Marketing Date | 19991122 |
| Marketing Category Name | ANDA |
| Labeler Name | Hospira Worldwide, Inc. |
| Substance Name | CYTARABINE |
| Strength Number | 100 |
| Strength Unit | mg/mL |
| Pharmaceutical Classes | Nucleic Acid Synthesis Inhibitors [MoA],Nucleoside Metabolic Inhibitor [EPC] |
